Pozelimab
Complement Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: pozelimab-bbfg, REGN3918, veopoz
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Pozelimab is a drug in the Complement Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as Complement Inhibitors. DrugCentral lists 1 molecular target, including C5. Recorded indications include CHAPLE disease.
- Drug class: Complement Inhibitor.
- Mechanism of action: Complement Inhibitors.
- Molecular targets: C5 (1 listed in DrugCentral).
- Indications: CHAPLE disease.
- ATC code: L04AJ11 (Complement inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- CHAPLE disease
Contraindications (1)
- Meningococcal infectious disease
Mechanism & targets
| Mechanism of action (MoA) | Complement Inhibitors |
|---|---|
| Established pharmacologic class | Complement Inhibitor |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Complement C5 | C5 | inhibitor | Kd 9.72 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-08-18 | FDA | — | REGENERON PHARMACEUTICALS | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AJ11 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 2096328-94-6 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Pozelimab used for?
DrugCentral lists the following indications for Pozelimab: CHAPLE disease.
How does Pozelimab work?
Pozelimab is classified as Complement Inhibitors; its molecular targets in DrugCentral include C5 (inhibitor).
When was Pozelimab first approved?
Pozelimab was first approved by the FDA in 2023.
What drug class does Pozelimab belong to?
Pozelimab is in the Complement Inhibitor class.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5740 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4298086 — compound record and bioactivity
- DrugBank DB15218 — drug record
- FDA UNII 0JJ21K6L2I — substance identity
- DailyMed: FDA labels for Pozelimab — current prescribing information (label search)
- UniProt P01031 (C5) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.